Pharmacological and neurosurgical management of cerebral palsy and dystonia: Clinical practice guideline update.
Journal
Developmental medicine and child neurology
ISSN: 1469-8749
Titre abrégé: Dev Med Child Neurol
Pays: England
ID NLM: 0006761
Informations de publication
Date de publication:
19 Apr 2024
19 Apr 2024
Historique:
revised:
26
02
2024
received:
06
07
2023
accepted:
01
03
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
19
4
2024
Statut:
aheadofprint
Résumé
Dystonia, typically characterized by slow repetitive involuntary movements, stiff abnormal postures, and hypertonia, is common among individuals with cerebral palsy (CP). Dystonia can interfere with activities and have considerable impact on motor function, pain/comfort, and ease of caregiving. Although pharmacological and neurosurgical approaches are used clinically in individuals with CP and dystonia that is causing interference, evidence to support these options is limited. This clinical practice guideline update comprises 10 evidence-based recommendations on the use of pharmacological and neurosurgical interventions for individuals with CP and dystonia causing interference, developed by an international expert panel following the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The recommendations are intended to help inform clinicians in their use of these management options for individuals with CP and dystonia, and to guide a shared decision-making process in selecting a management approach that is aligned with the individual's and the family's values and preferences.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : AACPDM
Organisme : Ontario Brain Institute
Organisme : Ward Family to the Holland Bloorview Kids Rehabilitation Hospital Foundation
Informations de copyright
© 2024 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press.
Références
Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863–73.
Sanger TD, Delgado MR, Gaebler‐Spira D, Hallett M, Mink JW, Disorders TFoCM. Classification and definition of disorders causing hypertonia in childhood. Pediatrics. 2003;111(1):e89‐e97.
Jethwa A, Mink J, Macarthur C, Knights S, Fehlings T, Fehlings D. Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children. Developmental Medicine & Child Neurology. 2010;52(5):e83‐e7.
National Institute of Neurological Disorders and Stroke. Dystonia Bethesda, MD: National Institute of Neurological Disorders and Stroke; [updated 2023 Jan 20; cited 2023 Feb 1]. Available from: https://www.ninds.nih.gov/health‐information/disorders/dystonia.
Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109(suppl 109):8–14.
Cans C, Dolk H, Platt MJ, Colver A. Recommendations from the SCPE collaborative group for defining and classifying cerebral palsy. Developmental medicine and child neurology. 2007;49:35.
Rice J, Skuza P, Baker F, Russo R, Fehlings D. Identification and measurement of dystonia in cerebral palsy. Developmental medicine and child neurology. 2017;59(12):1249–55.
Penner M, Xie WY, Binepal N, Switzer L, Fehlings D. Characteristics of pain in children and youth with cerebral palsy. Pediatrics. 2013;132(2):e407‐e13.
Monbaliu E, De La Peña MG, Ortibus E, Molenaers G, Deklerck J, Feys H. Functional outcomes in children and young people with dyskinetic cerebral palsy. Developmental Medicine & Child Neurology. 2017;59(6):634–40.
Fehlings D, Brown L, Harvey A, Himmelmann K, Lin JP, Macintosh A, et al. Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. Dev Med Child Neurol. 2018;60(4):356–66.
Kolaski K. Instructions for AACPDM Care Pathway Development.: Milwaukeee, WI: The American Academy for Cerebral Palsy and Developmental Mecidine; 2020.
Schünemann HJ, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. Cmaj. 2014;186(3):E123‐E42.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Bmj. 2008;336(7650):924–6.
Schlaggar BL, Mink JW. Movement disorders in children. Pediatrics in Review. 2003;24(2):39–51.
Sanger TD, Chen D, Fehlings DL, Hallett M, Lang AE, Mink JW, et al. Definition and classification of hyperkinetic movements in childhood. Movement Disorders. 2010;25(11):1538–49.
Allen NM, Lin JP, Lynch T, King MD. Status dystonicus: a practice guide. Developmental Medicine & Child Neurology. 2014;56(2):105–12.
Scalise R, Sgandurra G, Menici V, Capodagli N, Di Pietro R, Romeo DM, et al. A retrospective longitudinal study in a cohort of children with dyskinetic cerebral palsy treated with tetrabenazine. Frontiers in Neurology. 2021;12:612429.
Manji H, Howard R, Miller D, Hirsch N, Carr L, Bhatia K, et al. Status dystonicus: the syndrome and its management. Brain: a journal of neurology. 1998;121(2):243–52.
Bohn E, Goren K, Switzer L, Falck‐Ytter Y, Fehlings D. Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta‐analysis. Developmental Medicine and Child Neurology. 2021;63(9):1038–50.
Guyatt GH, Oxman AD, Kunz R, Falck‐Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ. 2008;336(7652):1049–51.
Lexicomp Online, Pediatric and Neonatal Lexi‐Drugs Online Waltham, MA: UptoDate, Inc.: Lexicomp, Inc.; [updated accessed 2022 Nov 4]. Available from: http://online.lexi.com.
Harvey A, Bear N, Rice J, Antolovich G, Waugh MC. National surveillance of oral medication prescription for children with dystonic cerebral palsy. Journal of Paediatrics and Child Health. 2021.
Lumsden DE, Crowe B, Basu A, Amin S, Devlin A, DeAlwis Y, et al. Pharmacological management of abnormal tone and movement in cerebral palsy. Arch Dis Child. 2019;104(8):775–80.
Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence‐based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336–43.
Navarrete‐Opazo AA, Gonzalez W, Nahuelhual P. Effectiveness of oral baclofen in the treatment of spasticity in children and adolescents with cerebral palsy. Archives of physical medicine and rehabilitation. 2016;97(4):604–18.
Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence‐based review including meta‐analysis of the effect of botulinum toxin and other cure options. European Journal of Neurology. 2004;11(6):361–70.
Goyal V, Laisram N, Wadhwa RK, Kothari SY. Prospective randomized study of oral diazepam and baclofen on spasticity in cerebral palsy. Journal of clinical and diagnostic research: JCDR. 2016;10(6):RC01.
Scheinberg A, Hall K, Lam LT, O'Flaherty S. Oral baclofen in children with cerebral palsy: A double‐blind cross‐over pilot study. Journal of paediatrics and child health. 2006;42(11):715–20.
Carranza‐del Rio J, Clegg NJ, Moore A, Delgado MR. Use of trihexyphenidyl in children with cerebral palsy. Pediatr Neurol. 2011;44(3):202–6.
Tsoi WSE, Zhang LA, Wang WY, Tsang KL, Lo SK. Improving quality of life of children with cerebral palsy: a systematic review of clinical trials. Child: Care Health Dev. 2011; 38(1): 21–31.
Masson R, Pagliano E, Baranello G. Efficacy of oral pharmacological treatments in dyskinetic cerebral palsy: a systematic review. Dev Med Child Neurol. 2017;59(12):1237–48.
Fasano A, Ricciardi L, Bentivoglio AR, Canavese C, Zorzi G, Petrovic I, et al. Status dystonicus: Predictors of outcome and progression patterns of underlying disease. Mov Disord. 2012; 27(6): 783–788.
Nakou V, Williamson K, Arichi T, Lumsden DE, Tomlin S, Kaminska M, et al. Safety and efficacy of high‐dose enteral, intravenous, and transdermal clonidine for the acute management of severe intractable childhood dystonia and status dystonicus: An illustrative case‐series. European Journal of Paediatric Neurology. 2017;21(6):823–32.
Ostojic K, Paget SP, Morrow AM. Management of pain in children and adolescents with cerebral palsy: a systematic review. Developmental Medicine & Child Neurology. 2019;61(3):315–21.
Liow NY‐K, Gimeno H, Lumsden DE, Marianczak J, Kaminska M, Tomlin S, et al. Gabapentin can significantly improve dystonia severity and quality of life in children. european journal of paediatric neurology. 2016;20(1):100–7.
Egunsola O, Wylie CE, Chitty KM, Buckley NA. Systematic review of the efficacy and safety of gabapentin and pregabalin for pain in children and adolescents. Anesthesia & Analgesia. 2019;128(4):811–9.
Arya R, Glauser TA. Pharmacotherapy of focal epilepsy in children: a systematic review of approved agents. CNS drugs. 2013;27(4):273–86.
Fairhurst C, Kumar R, Checketts D, Tayo B, Turner S. Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Dev Med Child Neurol. 2020.
Nielsen S, Murnion B, Campbell G, Young H, Hall W. Cannabinoids for the treatment of spasticity. Developmental Medicine & Child Neurology. 2019;61(6):631–8.
Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, et al. Cannabis‐based products for pediatric epilepsy: A systematic review. Epilepsia. 2019;60(1):6–19.
Lim K, See YM, Lee J. A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci. 2017;15(4):301.
McClelland VM, Fialho D, Flexney‐Briscoe D, Holder GE, Elze MC, Gimeno H, et al. Somatosensory Evoked Potentials and Central Motor Conduction Times in children with dystonia and their correlation with outcomes from Deep Brain Stimulation of the Globus pallidus internus. Clinical Neurophysiology. 2018;129(2):473–86.
Shah SA, Brown P, Gimeno H, Lin J‐P, McClelland VM. Application of Machine Learning Using Decision Trees for Prognosis of Deep Brain Stimulation of Globus Pallidus Internus for Children With Dystonia. Frontiers in neurology. 2020;11.
Monbaliu E, Ortibus E, De Cat J, Dan B, Heyrman L, Prinzie P, et al. The Dyskinesia Impairment Scale: a new instrument to measure dystonia and choreoathetosis in dyskinetic cerebral palsy. Developmental Medicine & Child Neurology. 2012;54(3):278–83.
Vanmechelen I, Danielsson A, Lidbeck C, Tedroff K, Monbaliu E, Krumlinde‐Sundholm L. The Dyskinesia Impairment Scale: Development, construct validity, and reliability. Developmental Medicine & Child Neurology. 2022.
Lorentzen J, Pradines M, Gracies J‐M, Nielsen JB. On Denny‐Brown's ‘spastic dystonia’–What is it and what causes it? Clinical Neurophysiology. 2018;129(1):89–94.
Lumsden DE. Spastic dystonia: Still a valid term. Developmental Medicine & Child Neurology. 2023.
Lin JP, Nardocci N. Recognizing the Common Origins of Dystonia and the Development of Human Movement: A Manifesto of Unmet Needs in Isolated Childhood Dystonias. Front Neurol. 2016;7:226.
Gimeno H, Farber J, Thornton J, Polatajko H. The Relative Merits of an Individualized Versus a Generic Approach to Rating Functional Performance in Childhood Dystonia. Children. 2021;8(1):7.
Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, Group DS. Rating scales for dystonia: a multicenter assessment. Movement disorders. 2003;18(3):303–12.
Haberfehlner H, Goudriaan M, Bonouvrié LA, Jansma EP, Harlaar J, Vermeulen RJ, et al. Instrumented assessment of motor function in dyskinetic cerebral palsy: a systematic review. Journal of neuroengineering and rehabilitation. 2020;17(1):1–12.
Bonouvrie LA, Haberfehlner H, Becher JG, Vles JS, Vermeulen RJ, Buizer AI, et al. Attainment of personal goals in the first year of intrathecal baclofen treatment in dyskinetic cerebral palsy: a prospective cohort study. Disabil Rehabil. 2023; 45(8): 1315–22.
Koy A, Kuehn AA, Huebl J, Schneider GH, van Riesen AK, Eckenweiler M, et al. Quality of Life After Deep Brain Stimulation of Pediatric Patients with Dyskinetic Cerebral Palsy: A Prospective, Single‐Arm, Multicenter Study with a Subsequent Randomized Double‐Blind Crossover (STIM‐CP). Mov Disord. 2022; 37(4): 799–811.